Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elorac, a specialty pharmaceutical company focused on the treatment of dermatological disorders, has reported results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea.
Subscribe to our email newsletter
Elorac said that in two phase III pivotal double-blind, randomised, vehicle-controlled, paired-comparison, multi-center studies, the results showed reductions in acne lesion counts after 8 and 12 weeks of treatment with CPO as compared to vehicle treatment.
Elorac president and CEO Jeffrey Bernstein said that CPO is an improvedn version of benzoyl peroxide (BPO), which is the most commonly used product for acne.
"The efficacy results for CPO are similar to those of previously approved topical acne products, but CPO has a distinct advantage in its tolerability," Bernstein said.
"We have clinical data comparing BPO and CPO in acne that demonstrates comparable efficacy, but documents significantly less local skin irritation in patients using CPO.
"We think that this superior tolerability also bodes well for the use of CPO in rosacea, where irritation is even more of an issue."